OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Rating of “Hold” by Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has been given an average recommendation of “Hold” by the five analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $6.3333.

A number of brokerages have commented on OKYO. Weiss Ratings reiterated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Tuesday, April 21st. Piper Sandler assumed coverage on OKYO Pharma in a research report on Friday, February 20th. They set an “overweight” rating and a $7.00 target price for the company.

Institutional Trading of OKYO Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in OKYO Pharma during the 4th quarter valued at about $36,000. Renaissance Technologies LLC raised its stake in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of OKYO Pharma during the third quarter worth approximately $31,000. 2.97% of the stock is owned by institutional investors.

OKYO Pharma Price Performance

Shares of OKYO Pharma stock opened at $1.62 on Friday. The firm has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.85. OKYO Pharma has a fifty-two week low of $1.44 and a fifty-two week high of $3.35.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.